Deals In Depth: January 2019
Executive Summary
Genentech signed a $2.3bn alliance with Adaptive Biotechnologies around neoantigen-directed T-cell therapies. Two major players in the industry, Bristol-Myers Squibb and Celgene, agreed to combine in a $74bn deal. KKR and Viking Global Investors co-led a nearly $300m investment in genetic disease company BridgeBio Pharma.
Potential deal value is the sum of up-front fees plus pre- and post-commercialization money.